新聞中心
關注我們
17 Dec
2018

知臨集團宣布完成首次公開募股

<BUSINESS WIRE>
(新聞只有英文版本)

Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced the closing of its initial public offering (“IPO” or the “Offering”) of 761,419 Class A Ordinary Shares, at a public offering price of $15.80 per share. The aggregate gross proceeds to Aptorum from the offering were $12,030,420, before deducting underwriting discounts and commissions and other offering expenses. While certain selling shareholders are offering to resell up to 1,595,235 Class A Ordinary Shares subject to certain lock-up periods, as applicable, none of the gross proceeds of the IPO will be used to purchase the selling shareholders’ securities nor will the Company receive any proceeds from the selling shareholders’ resale. The shares are expected to commence trading on The NASDAQ Global Market on December 18, 2018 at any time between 11:00 a.m. to 12:00 p.m. ET, under the ticker symbol “APM.”

Boustead Securities, LLC, China Renaissance Securities (HK) Limited, and AMTD Global Markets Limited acted as co-underwriters for the offering.

A registration statement has been filed with the SEC and became effective on December 3, 2018. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Boustead Securities, LLC, email: offerings@boustead1828.com or by calling +1 (949) 502-4409 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 265, Irvine, CA 92618, USA.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aptorum Group Limited

We are a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs. We have obtained exclusive licenses for our technologies. In addition, we are also developing certain proprietary technologies as product candidates. We are pursuing therapeutic and diagnostic projects (including projects seeking to use extracts or derivatives from natural substances to treat diseases) in neurology, infectious diseases, gastroenterology, oncology and other disease areas. We also have projects focused on surgical robotics. In addition, we opened a medical clinic, AML Clinic, in June 2018. Its initial focus is on treatment of chronic diseases resulting from modern sedentary lifestyles and aging population. For more information about the Company, please visit www.aptorumgroup.com.

About Boustead Securities, LLC

Boustead Securities, LLC ("Boustead") is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead's core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services. For more information, visit www.boustead1828.com.

About China Renaissance Securities (Hong Kong) Limited

China Renaissance (“CR”) is a leading financial institution that combines private placement advisory, M&A advisory, securities underwriting, research, sales and trading, investment management and other financial services. Providing one-stop financial services across mainland China, Hong Kong and the United States, CR operates a competitive and unique international network that connects China’s capital markets with the rest of the world, serving new economy entrepreneurs and investors globally. CR has offices in Beijing, Shanghai, Hong Kong and New York, with approximately 600 employees. As of March 31, 2018, CR had advised on approximately 700 transactions worth over US$100 billion since the inception, and CR had AUM of approximately US$4.1 billion in new economy investments. For more information, visit www.huaxing.com.

About AMTD Global Markets Limited

AMTD Global Markets Limited (“AMTD”) is a Hong Kong-based comprehensive financial institution dedicated to serving and bridging capital and resources across mainland China, Hong Kong and the globe. As one of the largest Hong Kong-based non-bank financial institution, AMTD has been widely recognized as a pre-eminent capital markets player with leading cross-border investment banking capabilities in Asia. Founded in 2003, AMTD has a long history of promoting technological innovations and the development of New Economy sectors, especially in the fields of FinTech, Artificial Intelligence and Healthcare. For more information, visit www.amtdgroup.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company's statements regarding listing on the NASDAQ Global Market and the completion of the IPO are forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, risks and uncertainties related to the satisfaction of the customary closing conditions related to the IPO and the listing on NASDAQ. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward‐looking statements to reflect events or circumstances that arise after the date hereof unless required by the applicable laws, regulations or rules.

Contacts
At the Company:
Sabrina Khan, CFO
Aptorum Group Limited
Phone: +852 2117 6611
Email: investor.relations@aptorumgroup.com

06 Dec
2018

知臨集團有限公司宣佈首次公開發售定價

<BUSINESS WIRE>

知臨集團有限公司(以下簡稱為「知臨」或「公司」),作為一家以地處香港、處於臨床前階段的醫藥研發企業,致力推進一系列嶄新醫療及診斷科技的研發和商品化,以應對未被滿足的醫療需求。公司於2018年12月3日宣佈,公司提交的關於其A類普通股的擬議首次公開發售(「首次公開發售」或「發售」)、每股面值1.00美元(「股份」)、其公開發售定價為每股15.80美元、集資規模至少為1,000萬美元、最高為3,000萬美元的表格F-1的登記聲明已被美國證券交易委員會(「SEC」)宣佈有效。公司最多可發售1,898,734股股份以及最多51,990股承銷商認股權證。相對而言,某些出售股東最多可發售1,595,235股股份(統稱「註冊證券」)。公開募股的所得款項不會用於購買出售股東的證券。公司股票預計將於2018年12月18日在納斯達克全球市場開始交易,股票交易代碼為APM。本次發售預計將於2018年12月12日或之前截止,具體截止日期取決於慣例成交條件。

此次發行將以最大努力原則發售。寶德證券有限公司,華興證券(香港)有限公司,以及尚乘環球市場有限公司將作為發售的聯席承銷商。

如上所述,公司已向美國證券交易委員會提交了與註冊證券(文件號:333-227198)有關的註冊聲明。此聲明已於2018年12月3日宣佈生效。此次發售僅通過書面招股說明書進行,該招股說明書為有效註冊聲明的一部分。您可以通過訪問美國證券交易委員會網站www.sec.gov上的EDGAR免費獲得招股說明書的副本。或者,您亦可以向寶德證券有限公司索取本次發行有關的招股說明書的副本,電子郵件請致:offerings@boustead1828.com 或致電+1 (949) 502-4409,或郵件請致:Equity Capital Markets, 6 Venture, Suite 265, Irvine, CA 92618, USA.

本新聞稿不構成出售任何公司證券的邀約或建議購買任何公司證券的招攬。本公司證券亦不得在沒有註冊或註冊豁免無法適用的情況下在美國進行邀約或出售。若根據其他州或司法權區的證券法規定,此等要約、招攬或銷售在依法登記或滿足資格之前屬於非法行為,則該等證券亦不得在這些州或司法權區域出售。

關於知臨集團有限公司

我們是一家以香港為基地、處於臨床前階段的製藥企業。目前正致力推進一系列醫療及診斷科技的研發和商品化,以應對未被滿足的醫療需求。我們已獲得我們技術的獨家許可。此外,我們還在開發某些專有技術作為候選產品。在神經內科,傳染病,胃腸科,腫瘤學和其他疾病領域,我們正在尋求治療和診斷項目(包括尋求使用天然提取物或其衍生物治療疾病的項目)。我們還有專注於手術機器人的項目。另外,我們於2018年6月創建了一家醫療診所,名為AML 診所,其最初針對的是治療由現代久坐不動的生活方式和人口老齡化引起的慢性病。更多信息,請瀏覽:www.aptorumgroup.com.

關於寶德證券有限公司

寶德證券有限公司(「寶德」)是一家在各種行業,地域和交易類型上為廣泛的客戶群執行和建議首次公開招股,並購,資本籌集和重組任務的投資銀行。寶德的核心價值主張是通過創新解決方案和強大執行能力來創造機遇。憑藉在美國和世界各地經驗豐富的專業人士,寶德的團隊行動高效並提供廣泛的高端金融建議和服務。更多信息,請瀏覽:www.boustead1828.com.

關於華興證券(香港)有限公司

華興證券(香港)有限公司(「華興證券」)是一家領先的集私募諮詢,併購諮詢,證券承銷,研究,銷售和交易,投資管理和其他金融服務於一體的金融機構。華興證券在中國大陸,香港和美國提供一站式金融服務,通過構建具有競爭性和獨特性的國際網絡,將中國的資本市場與世界其他地區連接起來,為全球的新經濟企業家和投資者提供服務。華興資本集團在北京、上海、香港和紐約設有辦公室,擁有近600位員工。截至2018年3月31日,華興資本集團已幫助客戶成功完成包括首次公開募股、並購和私募融資等超過700宗交易,交易總額逾1,000億美元,私募股權投資基金資產管理規模近41億美元。更多信息,請瀏覽:www.huaxing.com.

關於尚乘環球市場有限公司

尚乘環球市場有限公司(「尚乘」)是一家總部位於香港的綜合性金融機構,致力於在中國,香港和全球提供橋接資本和資源。作為香港最大的非銀行金融機構之一,尚乘已被公認為卓越的資本市場參與者,在亞洲擁有領先的跨境投資銀行業務。尚乘成立於2003年,在促進技術創新和新經濟板塊發展方面有著悠久的歷史,特別是在金融科技,人工智能和醫療保健領域。更多信息,請瀏覽:www.amtdgroup.com.

安全港聲明

本新聞稿包含1995年「私人證券訴訟改革法案」所定義的前瞻性陳述。前瞻性陳述包括有關計劃,目的,目標,策略,未來事件或表現的陳述,以及除歷史事實陳述之外的基本假設和其他陳述。當公司使用諸如「可能」,「將會」,「打算」,「應該」,「相信」,「期待」,「預期」,「計劃」,「估計」或類似的與歷史不相關的的表達時,此描述為前瞻性的陳述。具體而言,公司有關在納斯達克全球市場上市和完成首次公開募股的聲明均為前瞻性聲明。前瞻性陳述不能保證未來表現,並涉及可能導致實際結果與前瞻性陳述中討論的公司預期產生重大差異的風險和不確定性。這些陳述受到不確定性和風險的影響,包括但不限於與滿足與首次公開招股相關的慣例成交條件和納斯達克上市相關的風險和不確定性。基於這些原因,謹請投資者不要過分依賴本新聞稿中的任何前瞻性陳述。公司向美國證券交易委員會提交的文件中討論了其他因素,查閱請致www.sec.gov。除非適用的法律,法規或規則要求,公司沒有義務公開修改這些前瞻性陳述以反映在此新聞稿發佈日期之後出現的事件或情況。

Contacts
更多信息,請聯繫公司:
Sabrina Khan 首席財務總監
知臨集團有限公司
電話: +852 2117 6611
電子郵箱: investor.relations@aptorumgroup.com

https://www.businesswire.com/news/home/20181206006095/zh-HK/

×
×
×
×
使用條款

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.